Latest astrocytoma Stories
For patients with glioma, the most common primary brain tumor, new findings may explain why current therapies fail to eradicate the cancer.
TUSTIN, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc.
Missing, mutated genes occur simultaneously in unique set of pediatric brain tumors.
There was no substantial change in brain tumor incidence among adults 5 to 10 years after cell phone usage sharply increased.
TUSTIN, Calif., Dec. 2 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported completion of patient enrollment in a dose confirmation and dosimetry trial of CotaraÂ® in patients with relapsed glioblastoma multiforme (GBM), the deadliest form of brain cancer.
BOSTON, Mass. and TUSTIN, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc.
Malignant brain tumors often fail to respond to promising new medication. Researchers in Heidelberg have discovered a mechanism and a tumor marker for the development of this resistance.
A new technology involving the fusion of four different types of images into a 3-D map of a patientâ€™s brain has helped University of Cincinnati (UC) specialists successfully remove a fist-sized tumor from the brain of an Indiana woman.
- Dosimetry Study Results Show Greater Than 300-Fold More Radiation Delivered to Tumor as Compared to Other Normal Organs - - All Patients in the First Two Cohorts Have Met or Exceeded the Expected Median Survival Time for Recurrent GBM Patients - TORONTO and TUSTIN, Calif., June 16 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc.
- Of or relating to good digestion.